Home Alzheimer’s Disease Study Demonstrates Promise for Olaparib in Metastatic Castration-Resistant Prostate Cancer

Study Demonstrates Promise for Olaparib in Metastatic Castration-Resistant Prostate Cancer

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide (Xtandi) or abiraterone (Zytiga) and who had alterations in genes with a role in homologous recombination repair, olaparib (Lynparza) was found to be associated with longer progression-free survival (PFS) and improved measures of response and patient-reported end points than either enzalutamide or abiraterone, according to results from the phase III PROfound trial published in The New England Journal of Medicine

The randomized, open-label clinical trial also found that a benefit was observed in the overall trial population with an alteration in any of the prespecified genes with a direct or indirect role in homologous recombination repair. 

“In men with metastatic castration-resistant prostate cancer who had BRCA1BRCA2, or ATM mutations and who had disease…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments